TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33027156

Group type: EXPERIMENTAL
Intervention: Community mentor mother visits only
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Text messages only
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Preconception ART initiation
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Post-conception ART initiation
Number of subjects: 1275
Study: 36311525

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) - 1.5 mA, 20 min, 6 sessions in 2 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 39
Study: 34506596

Group type: EXPERIMENTAL
Intervention: Equol supplement
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 34748263

Group type: EXPERIMENTAL
Intervention: Weight-loss diet intervention
Number of subjects: 551
Study: 33108761

Group type: EXPERIMENTAL
Intervention: 12-week exercise programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33042934

Group type: EXPERIMENTAL
Intervention: Zero-time exercise (ZTEx) intervention
Number of subjects: 673

Group type: COMPARATOR
Intervention: Control group (healthy eating information)
Number of subjects: 673
Study: 34864830

Group type: EXPERIMENTAL
Intervention: Mindfulness mobile application (Headspace) used daily for at least 6 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waitlist control group (no application use)
Number of subjects: 56
Study: 32405884

Group type: EXPERIMENTAL
Intervention: Patient-specific instrument (PSI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (without PSI)
Number of subjects: 48
Study: 35847786

Group type: EXPERIMENTAL
Intervention: Prolong Life with Nine Turn Method (PLWNT) Qigong exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PLWNT intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: CBT intervention
Number of subjects: 90
Study: 32090464

Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anaesthetic (IPLA) with ropivacaine instillation followed by a 3-day infusion.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group receiving 0.9% saline solution.
Number of subjects: 60
Study: 37664793

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study: 33909227

Group type: EXPERIMENTAL
Intervention: School-based depression screening
Number of subjects: 88
Study: 34187845

Group type: EXPERIMENTAL
Intervention: CADe (GI Genius, Medtronic)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group (no CADe)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: CADe
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: CADe (pooled data from AID-1 and AID-2)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Level of examiner experience
Number of subjects: 660
Study: 32479703

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35903847

Group type: EXPERIMENTAL
Intervention: Five-step nutrition intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine nutrition management (Control)
Number of subjects: 78
Study: 33675342

Group type: EXPERIMENTAL
Intervention: VA-fortified rice (500 µg RAEs/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unfortified rice
Number of subjects: 70
Study: 35882364

Group type: EXPERIMENTAL
Intervention: TAU plus guided deprexis (TAU-PLUS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 69
Study: 33950370

Group type: EXPERIMENTAL
Intervention: Additional simulation training along with institutional training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional training only
Number of subjects: 50
Study: 35175208

Group type: EXPERIMENTAL
Intervention: Facebook group intervention (CAN Quit) designed to promote evidence-based smoking cessation resources
Number of subjects: 0
Study: 32785044

Group type: EXPERIMENTAL
Intervention: Be Healthe for your Heart, a web‐based behavioral intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control, access to the National Heart Foundation website
Number of subjects: 31
Study: 36030153

Group type: EXPERIMENTAL
Intervention: Normoglycemia checklist applied preoperatively, intraoperatively, and postoperatively with continuous insulin infusion to maintain blood glucose levels between 80 to 150 mg/dl for 48 hours postoperative
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine practice available in the clinic (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33535212

Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetate dialysate (AD)
Number of subjects: 0
Study: 32320729

Group type: COMPARATOR
Intervention: FS (500 ppm F- + 800 ppm Sn2+ - positive control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FS + Carbopol (0.1% Carbopol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrapure water (negative control)
Number of subjects: 60
Study: 35436142

Group type: EXPERIMENTAL
Intervention: Mannitol (20 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 34359097

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 92/22 μg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Salbutamol 400 μg
Number of subjects: 93
Study: 32540725

Group type: EXPERIMENTAL
Intervention: Sinacurcumin® 80 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34235862

Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 574

Group type: COMPARATOR
Intervention: No TB treatment
Number of subjects: 574
Study: 33743390

Group type: EXPERIMENTAL
Intervention: Binary rhythm protocol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quaternary rhythm protocol
Number of subjects: 31
Study: 33220326

Group type: EXPERIMENTAL
Intervention: L-menthol mouthwash
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 22
Study: 36192209

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard of Care (SOC): plasmapheresis/intravenous immunoglobulin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 11
Study: 33196921

Group type: EXPERIMENTAL
Intervention: 177Lu-lilotomab satetraxetan
Number of subjects: 16
Study: 36460023

Group type: EXPERIMENTAL
Intervention: Free HIV self-test kit (BT group)
Number of subjects: 10111

Group type: COMPARATOR
Intervention: No free HIV self-test kit (nBT group)
Number of subjects: 10111
Study: 35802483

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (1.5 μg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: PO acetaminophen/hydrocodone (0.15 mg/kg)
Number of subjects: 34
Study: 32488435

Group type: EXPERIMENTAL
Intervention: Advanced pneumatic compression device (APCD) used once per day (instead of prescribed twice per day).
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lymphedema self-management (standard of care).
Number of subjects: 49
Study: 32512262

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 108
Study: 35772416

Group type: EXPERIMENTAL
Intervention: Suspend methotrexate group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Continue methotrexate group
Number of subjects: 254
Study: 34468814

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inorganic salt particles exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: HVO exhaust with aftertreatment exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: HVO exhaust without aftertreatment exposure
Number of subjects: 0
Study: 35287662

Group type: EXPERIMENTAL
Intervention: Ethics Quarter (EQ) e-learning intervention
Number of subjects: 95
Study: 34758887

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) induction, n = 20
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) induction, n = 17
Number of subjects: 37

Group type: COMPARATOR
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 37
Study: 36115962

Group type: EXPERIMENTAL
Intervention: Mobile application (reminder app)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No mobile application (control group)
Number of subjects: 53
Study: 33368358

Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 0
Study: 34787383

Group type: EXPERIMENTAL
Intervention: Direct osteopathic primary care sports medicine intervention (n=18)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group without active intervention (n=19)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall team performance during the intervention season
Number of subjects: 23
Study: 35039206

Group type: EXPERIMENTAL
Intervention: Sunscreen with photolyase (SC+P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular sunscreen (SC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical antioxidants (AOx)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 40
Study: 33556442

Group type: EXPERIMENTAL
Intervention: LDL-C
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: TGs
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: Lipid trait genetic variants
Number of subjects: 300000
Study: 32209712

Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer
Number of subjects: 217

Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 217
Study: 35066706

Group type: EXPERIMENTAL
Intervention: Text messages
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 25

Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 25
Study: 32434773

Group type: EXPERIMENTAL
Intervention: Standardised patient approach
Number of subjects: 52
Study: 33970846

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon alpha (rhIFN‐α) nasal drops for one month in the low-risk group
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon alpha (rhIFN‐α) nasal drops coupled with thymosin‐α1 in the high-risk group
Number of subjects: 2944
Study: 33089293

Group type: EXPERIMENTAL
Intervention: Bio-Oss bone powder with Heal-All Oral repair membrane
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bio-Oss collagen
Number of subjects: 26
Study: 35326273

Group type: EXPERIMENTAL
Intervention: Acoustic Coordinated Reset (CR®) Neuromodulation using the T30 neurostimulator with proprietary sound sequence
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo algorithm of the T30 neurostimulator
Number of subjects: 100
Study: 35260261

Group type: EXPERIMENTAL
Intervention: Patient experience story (bad story)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Patient experience story (neutral story)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Patient experience story (good story)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Intra-rater reliability
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Patient experience story (bad/neutral)
Number of subjects: 809
Study: 33630072

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 32361265

Group type: EXPERIMENTAL
Intervention: Necuparanib (5 mg/kg subcutaneous injection once daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Necuparanib
Number of subjects: 110
Study: 33668849

Group type: EXPERIMENTAL
Intervention: 400 mg/day algal docosahexaenoic acid (DHA)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Placebo (two microencapsulated soy and corn oil tablets)
Number of subjects: 957
Study: 32379216

Group type: EXPERIMENTAL
Intervention: Improved Gengnianchun (I-GNC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 36477779

Group type: EXPERIMENTAL
Intervention: Bladder training (drinking water multiple times and retaining urine for three days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (regular drinking and urination habits without special instructions)
Number of subjects: 150
Study: 32336696

Group type: EXPERIMENTAL
Intervention: Statin + Probucol + Cilostazol
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Statin + Probucol
Number of subjects: 281

Group type: COMPARATOR
Intervention: Statin alone
Number of subjects: 281
Study: 35176038

Group type: EXPERIMENTAL
Intervention: Evocalcet with intravenous vitamin D receptor activator (low dose < 1.5 μg)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Evocalcet with intravenous vitamin D receptor activator (high dose ≥ 1.5 μg)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Evocalcet with intravenous vitamin D receptor activator (all groups)
Number of subjects: 253
Study: 34721802

Group type: EXPERIMENTAL
Intervention: General Medicine (GM) rotation
Number of subjects: 386

Group type: COMPARATOR
Intervention: Intensive Care Unit (ICU) rotation
Number of subjects: 386
Study: 32964624

Group type: EXPERIMENTAL
Intervention: FA‐treatment with in-session exposure (FA‐ISE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: FA‐treatment without in-session exposure (FA)
Number of subjects: 90
Study: 35728577

Group type: EXPERIMENTAL
Intervention: CAF + L‐PRF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CAF + A‐PRF
Number of subjects: 30
Study: 32124801

Group type: EXPERIMENTAL
Intervention: SNP genes RLN2 (rs4742076, rs3758239)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IL4 (rs2243250)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IL10 (rs1800872)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TLR2 gene expression
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TLR4 gene expression
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FoxP3 expression
Number of subjects: 100
Study: 35300258

Group type: EXPERIMENTAL
Intervention: Task-specific training based on motor relearning program (MRP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional physical therapy program (CPT)
Number of subjects: 66
Study: 32199708

Group type: COMPARATOR
Intervention: Fluid restriction alone (FR)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fluid restriction and furosemide (FR+FM)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fluid restriction, furosemide, and NaCl (FR+FM+NaCl)
Number of subjects: 92
Study: 34357505

Group type: EXPERIMENTAL
Intervention: Very Low-Energy Diet (VLED) for 2 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance diets for 10 months
Number of subjects: 42
Study: 32503657

Group type: EXPERIMENTAL
Intervention: Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, for a maximum of 14 days plus routine treatment for COVID-19.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Regular treatment for patients with COVID-19, including oxygen therapy and drugs that reduce phlegm and relieve cough.
Number of subjects: 210
Study: 36281496

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 8 mg BID
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 8 mg QD
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 32 mg QD
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 32 mg BID
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 16 mg QD
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 16 mg BID
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ORMD‐0801 32 mg TID
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 36243884

Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy (MSDP)
Number of subjects: 572

Group type: COMPARATOR
Intervention: No maternal smoking during pregnancy (Control)
Number of subjects: 572
Study: 34711436

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c), 7.5 µg hemagglutinin antigen per dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c)
Number of subjects: 0
Study: 34635114

Group type: EXPERIMENTAL
Intervention: Carglumic acid with standard treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 38
Study: 33105245

Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 146
Study: 35922611

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) group - 3-month physical training starting 6 weeks after BS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group - no specific activity
Number of subjects: 20
Study: 32217274

Group type: EXPERIMENTAL
Intervention: Fibular reposition taping (FRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham taping
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study: 36168738

Group type: EXPERIMENTAL
Intervention: NeuFlex implant
Number of subjects: 72

Group type: COMPARATOR
Intervention: Integra implant
Number of subjects: 72
Study: 33809720

Group type: EXPERIMENTAL
Intervention: Bell pepper extract enriched for rhamnogalacturonan-I (bpRG-I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carrot extract enriched for rhamnogalacturonan-I (cRG-I)
Number of subjects: 0
Study: 33373691

Group type: EXPERIMENTAL
Intervention: High calorie shake
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low calorie shake
Number of subjects: 99
Study: 33429977

Group type: EXPERIMENTAL
Intervention: 7 g xylitol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 17 g xylitol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 35 g xylitol
Number of subjects: 12

Group type: COMPARATOR
Intervention: tap water (control)
Number of subjects: 12
Study: 33378441

Group type: EXPERIMENTAL
Intervention: APC flash‐free brackets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional ceramic brackets
Number of subjects: 30
Study: 34782915

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) coupled with inverse phase rotatory chair impulse in sinusoidal harmonic acceleration protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) coupled with inverse phase rotatory chair impulse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 30
Study: 33573042

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (142 mg EPA, 267 mg DHA, 12 mg vitamin E, 5 µg vitamin D, six capsules twice a day for three weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32574801

Group type: EXPERIMENTAL
Intervention: Autogenous Obsessions (AOs)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reactive Obsessions (ROs)
Number of subjects: 70
Study: 34865513

Group type: EXPERIMENTAL
Intervention: Recommendations for conducting and interpreting cardiac surgery trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial interventions and study end points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completeness of follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial design and analytic techniques
Number of subjects: 0
Study: 32271672

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously once every 3 weeks for up to 24 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 36176007

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation program conducted weekly for 12 weeks in addition to usual care
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study: 33758119

Group type: EXPERIMENTAL
Intervention: Substance-exposed newborn vignette with injection heroin use
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Substance-exposed newborn vignette with prescription opioid use
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Responses regarding mother's responsibility
Number of subjects: 1227
Study: 34687446

Group type: EXPERIMENTAL
Intervention: Fremanezumab (monthly or quarterly)
Number of subjects: 50
Study: 35276884

Group type: EXPERIMENTAL
Intervention: Dietary fibre supplementation (19.2 g/day) for 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-responders to fibre treatment
Number of subjects: 0
Study: 32671515

Group type: EXPERIMENTAL
Intervention: Healthy eating intervention
Number of subjects: 299

Group type: COMPARATOR
Intervention: HPV vaccination (control)
Number of subjects: 299
Study: 36040741

Group type: EXPERIMENTAL
Intervention: Remote care (initial in-home visit followed by daily video visit facilitated by the home hospital nurse)
Number of subjects: 172

Group type: COMPARATOR
Intervention: In-home physician care (control group)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Remote care
Number of subjects: 172
Study: 33257104

Group type: EXPERIMENTAL
Intervention: Anti-TT IgG in oral fluid (OF)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Total IgG in oral fluid specimens
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: High oral fluid volume and sucking on the swab
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Total IgG
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Post hoc adjustments for OF volume and total IgG concentration
Number of subjects: 267
Study: 33487050

Group type: EXPERIMENTAL
Intervention: Education-based intervention with an educational session and AdhereTech smart bottle with reminder functions activated
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention control with a session on general eye health and a smart bottle without reminder functions activated
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Education-based intervention
Number of subjects: 200